*|MC:SUBJECT|* http://www.eiseverywhere.com/emarketing/view.php?id=3WXi9zVSFrE5p3tZ0ngilw%3D%3D
https://tatcongress.org/registration-2/ Join this highly targeted conference covering the most promising new drugs and cancer targets under development in early phase clinical and translational research, as well as drugs close to entering clinical development. https://tatcongress.org/registration-2/ https://tatcongress.org/abstract-submission/ We invite you to submit your abstract for presentation at the TAT 2017 Congress. Abstracts on a wide range of topics in the field of targeted therapy for cancer are welcome. The deadline for abstract submission is January 6, 2017. Abstracts accepted for presentation will be published in an indexed oncology journal. https://tatcongress.org/abstract-submission/ https://tatcongress.org/tat-2017-congress-profile/phase-1-trials-in-drug-development-2017/ Under the chairmanship of professor Jean-Charles Soria, Goustave Roussy Cancer Center, the plenary sessions of the 15th ‘International Congress on Targeted Anticancer Therapies’ will cover the following themes: * Opening Ceremony with TAT 2017 https://tatcongress.org/tat-honorary-award-lecture-2017/ and Keynote Lecture * Immune-Oncology (1): Novel combinations and biomarkers * Immuno-oncology (2): Novel immune modulators * Phase 1 studies – Completed or in progress * Early-phase drug development in hematology * Targeting the cell cycle * Targeting cancer metabolism * Targeted drug delivery: Next-generation antibody-drug conjugates and nanoparticles * Clinical genomic profiling in early-phase clinical studies * New androgen receptor inhibitors in prostate cancer * New cytotoxic agents * Miscellaneous drugs and targets The poster sessions will provide an even wider range of topics in the field of targeted drug development and related areas of research. Check the list of https://tatcongress.org/abstract-submission-2017/abstract-submission-will-open-soon-tat-2017/ for more information on abstract and poster topics. https://tatcongress.org/tat-2017-congress-profile/key-characteristics-2017/ * Focus at early-phase development and translational research of new molecular and immunological targets * Invited lectures by top-level faculty, including phase 1 investigators having hands-on experience with the new agents * Highly international participation from across the globe * Medium-sized meeting offering plenary sessions only * Excellent networking opportunities in a confined setting * Accredited learning for medical specialists https://tatcongress.org/tat-2017-congress-profile/committees-tat-2016/ Jean-Charles Soria, FR; President Giuseppe Giaccone, USA Gail Eckhardt, USA Lee Ellis, USA Marinus Lobbezoo, NL Josep Tabernero, ES Alexander Eggermont, FR https://tatcongress.org/tat-2017-congress-profile/committees-tat-2016/ Michael Atkins, USA Jean-Pierre Armand, FR Udai Banerji, UK Susan Bates, USA Philippe Bedard, CAN Hilary Calvert, UK Filippo de Braud, IT Kapil Dhingra, USA Keith Flaherty, USA Roch Houot, FR David Hyman, USA Jeffrey Infante, USA Antoine Italiano, FR Filip Janku, USA Shivaani Kummar, USA Ulrik Lassen, DK Martijn Lolkema, NL Patricia LoRusso, USA Aurelien Marabelle, FR Christophe Massard, FR Peter O’Dwyer, USA Arne Östman, SWE Michael Pishvaian, USA Ruth Plummer, UK Yves Pommier, USA Vincent Ribrag, FR Jordi Rodon, ES Gary Schwartz, USA Lesley Seymour, CAN Geoffrey Shapiro, USA Anthony Tolcher, USA Giorgio Trinchieri, USA John Wright, USA https://tatcongress.org/general-information/venue-2/ http://www.marriott.com/hotels/travel/parst-paris-marriott-rive-gauche-hotel-and-conference-center/ 17 Boulevard Saint Jacques Paris, 75014 France https://www.eiseverywhere.com/emarketing/profile.php?id=32UjxGIsRLgsLRpBX7OEpd6McBnNP97rbkf8P549GJr9qrHizWeUqK%2BMxCxwtwV9
